A multicentre, double blind, parallel group, phase IIa clinical trial to assess the efficacy and safety of Cpn10 administered as twice weekly intravenous injections in subjects with rheumatoid arthritis.

Trial Profile

A multicentre, double blind, parallel group, phase IIa clinical trial to assess the efficacy and safety of Cpn10 administered as twice weekly intravenous injections in subjects with rheumatoid arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs INV 103 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors CBio
  • Most Recent Events

    • 29 Aug 2011 Actual initiation date (Aug 2005) added as reported by Australian New Zealand Clinical Trials Registry.
    • 29 Aug 2011 Additional trial identifiers (ACTRN12606000041550, 001022) identified, inclusion and exclusion criteria amended and addititional trial centers identified as reported by Australian New Zealand Clinical Trials Registry.
    • 29 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12606000041550).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top